Quantitative analysis of AAV capsid heterogeneity with mass photometry
Cell & Gene Therapy Insights 2025; 11(5), 715
DOI: 10.18609/cgti.2025.079
Published: 14 July
FastFacts
![]() | Ensuring the efficacy and regulatory compliance of AAV-based gene therapies depends on critical quality attributes such as purity, potency, and safety. However, AAV preparations are often heterogeneous, containing capsid-related impurities that can reduce therapeutic effectiveness and increase production costs. This poster highlights how to achieve fast and accurate mass photometer analysis for characterizing AAV populations.
|